SBIR Phase I: Development of Agents to Promote Cellular Ga-67 (Gallium-67) Uptake

点击翻译按钮获取中文摘要

This Small Business Innovation Research (SBIR) Phase I project is proposes to develop new pharmaceutical agents to selectively enhance tumor imaging using gallium (Ga-67). Ga-67 has been widely used in tumor imaging and clinical medicine due to significant advantages in terms of low cost, ease of use and long life. However, the use of Ga -67 is currently limited, mainly due to varying tumor avidity and high dose requirements needed to achieve high signal-to-background ratios in non-gallium avid tumors. Increasing the selective uptake of gallium by tumor cells will dramatically improve gallium imaging, resulting in the development of an innovative, sensitive, and low-cost tumor detection tool. This Phase I program will focus on designing, preparing and evaluating novel nitrosipine derivatives with the potential to drastically increase the uptake of Ga-67 by tumor cells. The commercial application of this project is in the area of tumor imaging and oncology.